|
| 2009 | 2012 | P value |
| (N = 14) | (N = 17) | ||
| Introduction of LADG (n, yes/no/unknown) | 5/9/0 | 12/5/0 | 0.11‡ |
| Patients for whom LADG was indicated (n, %) |
|
|
|
| cMN0 | 0 (0) | 0 (0) | 0.98‡ |
| IA | 6 (60.0) | 8 (50.0) | |
| IB | 3 (30.0) | 6 (37.5) | |
| II | 1 (10.0) | 2 (12.5) | |
| Extent of lymph node dissection in patients undergoing LADG (n, yes/no/unknown) | 2/10/2 | 0/14/3 | 0.27† |
| Reconstruction in patients undergoing LADG (n, %) |
|
|
|
| Billroth I | 8 (57) | 8 (53) | 0.97‡ |
| Billroth I/Roux-en-Y | 4 (29) | 6 (40) | |
| Billroth I/Billroth II | 2 (14) | 1 (7) | |
| Duration of LADG surgery (hours), mean ± SD | 4.35 ± 0.99 | 4.05 ± 0.81 | 0.57† |
| Average length of hospital stay after LADG (day), mean ± SD | 12.1 ± 2.25 | 15.25 ± 2.61 | 0.03*† |
| LADG-related increase in the incidence of complications (n, yes/no/unknown) | 0/4/10 | 2/8/7 | 1.00‡ |
| Could LADG become a standard treatment in the future? (n, yes/no/unknown) | 7/7/0 | 13/1/3 | 0.03*‡ |